Effectiveness of a Procalcitonin Algorithm to Guide Antibiotic Therapy in Respiratory Tract Infections Outside of Study Conditions: a Post-study Survey

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2009 Dec 30

PMID 20039090

Citations 28

Authors

P Schuetz

M Batschwaroff

F Dusemund

W Albrich

U Burgi

M Maurer

M Brutsche

A R Huber

B Muller

Affiliations

Soon will be listed here.

Abstract

All published evidence on procalcitonin (PCT)-guided antibiotic therapy was obtained in trials where physicians knew that they were being monitored, possibly resulting in higher adherence to the PCT algorithm. This study investigates the effectiveness of PCT guidance in an observational quality control survey. We monitored antibiotic therapy and algorithm adherence in consecutive patients with respiratory tract infections admitted to the Kantonsspital Aarau, Switzerland, between May 2008 and February 2009. The results were compared to the site-specific results of the former ProHOSP study. Overall and more pronounced for patients with community-acquired pneumonia, the median duration of antibiotic treatment in this survey was shorter than the ProHOSP control patients (6 vs. 7 days, P = 0.048 and 7 vs. 9 days, P < 0.001). In 72.5% of patients, antibiotics were administered according to the prespecified PCT algorithm. No significant differences concerning adverse medical outcome could be detected. This study mirrors the use of PCT-guided antibiotic therapy in clinical practice, outside of trial conditions. If algorithm adherence is reinforced, antibiotic exposure can be markedly reduced with subsequent reduction of antibiotic-associated side effects and antibiotic resistance. The integration of the PCT algorithm into daily practice requires ongoing reinforcement and involves a learning process of the prescribing physicians.

Citing Articles

Role of biomarkers in antimicrobial stewardship: physicians' perspectives.

Seok H, Park D Korean J Intern Med. 2024; 39(3):413-429.

PMID: 38715231 PMC: 11076897. DOI: 10.3904/kjim.2023.558.

Use of Biomarkers to Improve 28-Day Mortality Stratification in Patients with Sepsis and SOFA ≤ 6.

Baldira J, Ruiz-Rodriguez J, Ruiz-Sanmartin A, Chiscano L, Cortes A, Angeles Sistac D Biomedicines. 2023; 11(8).

PMID: 37626646 PMC: 10452503. DOI: 10.3390/biomedicines11082149.

Antimicrobial Stewardship Using Biomarkers: Accumulating Evidence for the Critically Ill.

Kyriazopoulou E, Giamarellos-Bourboulis E Antibiotics (Basel). 2022; 11(3).

PMID: 35326830 PMC: 8944654. DOI: 10.3390/antibiotics11030367.

Seeking diagnostic and prognostic biomarkers for childhood bacterial pneumonia in sub-Saharan Africa: study protocol for an observational study.

Valim C, Olatunji Y, Isa Y, Salaudeen R, Golam S, Knol E BMJ Open. 2021; 11(9):e046590.

PMID: 34593486 PMC: 8487183. DOI: 10.1136/bmjopen-2020-046590.

Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study.

Williams E, Mair L, de Silva T, Green D, House P, Cawthron K J Hosp Infect. 2021; 110:103-107.

PMID: 33484783 PMC: 7817391. DOI: 10.1016/j.jhin.2021.01.006.

References

Niederman M, Mandell L, Anzueto A, Bass J, Broughton W, Campbell G . Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001; 163(7):1730-54. DOI: 10.1164/ajrccm.163.7.at1010. View

Calverley P, Walker P . Chronic obstructive pulmonary disease. Lancet. 2003; 362(9389):1053-61. DOI: 10.1016/s0140-6736(03)14416-9. View

Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C . Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res. 2007; 7:102. PMC: 1947969. DOI: 10.1186/1472-6963-7-102. View

Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Leven M . Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005; 26(6):1138-80. DOI: 10.1183/09031936.05.00055705. View

Nobre V, Harbarth S, Graf J, Rohner P, Pugin J . Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2007; 177(5):498-505. DOI: 10.1164/rccm.200708-1238OC. View

Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I . Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009; 302(10):1059-66. DOI: 10.1001/jama.2009.1297. View

Schuetz P, Christ-Crain M, Muller B . Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype?. Swiss Med Wkly. 2009; 139(23-24):318-26. DOI: 10.4414/smw.2009.12584. View

Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber P . Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174(1):84-93. DOI: 10.1164/rccm.200512-1922OC. View

Juurlink D, Mamdani M, Lee D, Kopp A, Austin P, Laupacis A . Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351(6):543-51. DOI: 10.1056/NEJMoa040135. View

10.

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

11.

Lee R, Lindstrom S . A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology. 2007; 12(5):754-8. DOI: 10.1111/j.1440-1843.2007.01121.x. View

12.

Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M . Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004; 363(9409):600-7. DOI: 10.1016/S0140-6736(04)15591-8. View

13.

Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P . Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners.... BMC Fam Pract. 2005; 6:34. PMC: 1190167. DOI: 10.1186/1471-2296-6-34. View

14.

Anthonisen N, Manfreda J, Warren C, Hershfield E, Harding G, Nelson N . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106(2):196-204. DOI: 10.7326/0003-4819-106-2-196. View

15.

Pitt B, Zannad F, Remme W, Cody R, CASTAIGNE A, Perez A . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709-17. DOI: 10.1056/NEJM199909023411001. View

16.

Gonzales R, Sande M . Uncomplicated acute bronchitis. Ann Intern Med. 2000; 133(12):981-91. DOI: 10.7326/0003-4819-133-12-200012190-00014. View

17.

Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C . Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007; 131(1):9-19. DOI: 10.1378/chest.06-1500. View